Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Antioxidants : Nature's Defense Against Disease
| Antioxidants : Nature's Defense Against Disease |
| Autore | Sindhu Rakesh K |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Newark : , : John Wiley & Sons, Incorporated, , 2025 |
| Descrizione fisica | 1 online resource (667 pages) |
| Altri autori (Persone) |
SinghInderbir
BabuM. Arockia |
| Soggetto topico |
Antioxidants - Health aspects
Cancer - Prevention |
| ISBN |
9781394270552
1394270550 9781394270576 1394270577 9781394270569 1394270569 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover -- Series Page -- Title Page -- Copyright Page -- Contents -- Preface -- Chapter 1 Basics of Antioxidants and Their Importance -- Abbreviations -- 1.1 Introduction -- 1.2 Generalization of Antioxidant -- 1.3 Reactive Oxygen Species (ROS) and Free Radicals -- 1.4 Importance of Antioxidant in Medicine -- Conclusion -- References -- Chapter 2 Antioxidants in Cancer Prevention -- 2.1 Introduction -- 2.2 Free Radicals -- 2.2.1 Types of Free Radicals -- 2.2.2 Sources of Free Radicals -- 2.2.3 Free Radical Roles in Cancer Development -- 2.3 Antioxidants -- 2.3.1 Antioxidants from Fruits -- 2.3.1.1 Apple -- 2.3.1.2 Banana -- 2.3.1.3 Berries -- 2.3.1.4 Grapes -- 2.3.1.5 Kiwi -- 2.3.1.6 Orange -- 2.3.1.7 Papaya -- 2.3.1.8 Pomegranate -- 2.3.1.9 Watermelon -- 2.3.2 Antioxidants from Vegetables -- 2.3.2.1 Tomato -- 2.3.2.2 Chili -- 2.3.2.3 Potato -- 2.3.2.4 Vegetables from Cruciferae Family -- 2.3.2.5 Vegetables of the Cucurbitaceae Family -- 2.3.2.6 Beetroot -- 2.3.2.7 Beta-Carotene from Fruits and Vegetables -- 2.3.2.8 Lutein and Zeaxanthin from Fruits and Vegetables -- 2.3.3 Antioxidants from Herbs and Spices -- 2.3.3.1 Garlic -- 2.3.3.2 Onion -- 2.3.3.3 Turmeric and Curcumin -- 2.3.3.4 Clove and Eugenol -- 2.3.3.5 Black Pepper and Piperine -- 2.3.3.6 Fenugreek -- 2.3.3.7 Ginger and Gingerol -- 2.3.4 Antioxidants from Vitamins and Minerals -- 2.4 Roles of Antioxidants in Cancer Prevention -- 2.5 Can Antioxidant Supplements Help to Prevent Cancer? -- 2.6 Pharmacokinetics of Antioxidants -- 2.7 Safety Assessment -- 2.8 Antioxidants can be Pro-Oxidants -- 2.9 Quality Control of Antioxidant Supplements -- 2.10 Conclusions -- References -- Chapter 3 Antioxidants in Inflammatory Diseases -- 3.1 Introduction -- 3.2 Inflammatory Disease: An Overview, Definition and Classification of Inflammatory Diseases.
3.3 Pathogenesis of Inflammation, Role of Oxidative Assault in Inflammatory Disease Development -- 3.3.1 Pathogenesis of Inflammation -- 3.3.2 Role of Oxidative Assault in Inflammatory Disease Development -- 3.4 Introduction to Antioxidants, Definition and Classification of Antioxidants, Mechanisms of Antioxidant Action, Sources of Dietary Antioxidants -- 3.4.1 Classification of Antioxidants -- 3.4.2 Mechanisms of Antioxidant Action of Antioxidant -- 3.4.2.1 Scavenging Free Radicals -- 3.4.2.2 Metal Chelation -- 3.4.3 Mechanism of Metal Chelation -- 3.4.3.1 Binding Affinity -- 3.4.3.2 Chelation Process -- 3.4.3.3 Preventing ROS Formation -- 3.5 Enzymatic Activity -- 3.5.1 Mechanism of Enzymatic Activity -- 3.5.1.1 Significance in Cellular Defense -- 3.6 Sources of Dietary Antioxidants -- 3.6.1 Fruits and Vegetables -- 3.6.2 Nuts and Seeds -- 3.6.3 Whole Grains -- 3.6.4 Herbs and Spices -- 3.6.5 Tea and Coffee -- 3.6.6 Dark Chocolate -- 3.6.7 Fatty Fish -- 3.7 Mechanisms of Oxidative Assault in Inflammatory Disease -- 3.7.1 Generation of ROS and RNS -- 3.7.2 Sources of Oxidative Assault in Inflammatory Disease -- 3.7.3 Cellular Targets of Oxidative Damage in Inflammatory Disease -- 3.8 Antioxidants and Inflammatory Disease -- 3.8.1 Antioxidants and Regulation of Inflammatory Signaling Pathways (MAPK Pathways Like ERK, JNK, and p38 MAPK) -- 3.8.2 Antioxidants and Modulation of Immune Cell Function (Shifting Macrophages from M1 to M2) -- 3.8.3 Antioxidants and Oxidative Assault Reduction -- 3.9 Antioxidants in Specific Inflammatory Diseases -- 3.9.1 Rheumatoid Arthritis (RA) and Antioxidant Interventions -- 3.9.1.1 Therapeutic Antioxidants for Rheumatoid Arthritis -- 3.9.2 Inflammatory Bowel Disease and Antioxidant Therapies -- 3.9.2.1 Enzymatic and Extracellular Antioxidant for IBD -- 3.9.2.2 Hormonal Therapy for IBD. 3.9.3 Atherosclerosis and the Role of Antioxidants -- 3.9.3.1 Enzymatic ROS Generation in Atherosclerosis -- 3.10 Therapeutic Strategies Targeting Oxidative Assault -- 3.11 Challenges and Future Directions -- 3.12 Conclusion -- References -- Chapter 4 Antioxidants in Cardiovascular Disease: Molecular Interaction and Therapeutic Implications -- 4.1 Introduction -- 4.2 Oxidative Assault and Cardiovascular Health -- 4.2.1 The Consequences of Oxidative Assault on the Physiology of the CVDs -- 4.2.2 Pathological Implications of Oxidative Assault in CVDs -- 4.2.2.1 NADPH Oxidases (NOX) -- 4.2.2.2 Endothelial Dysfunction -- 4.2.2.3 Mitochondrial Oxidative Assault -- 4.3 Oxidative Assault and Association with CVDs -- 4.3.1 Myocardial Ischemia-Reperfusion (I/R) Injury and Oxidative Assault -- 4.3.2 Heart Failure (HF) and Oxidative Assault -- 4.3.3 Atherosclerosis and Oxidative Assault -- 4.3.4 Atrial Fibrillation (AF) and Oxidative Assault -- 4.3.5 Hypertension and Oxidative Assault -- 4.4 Antioxidants and Their Sources -- 4.4.1 The Antioxidant Potential of Nuts -- 4.4.2 Morus alba-Induced Endothelial Vasorelaxation -- 4.4.3 White Mulberries Induced Increased eNOS Expression -- 4.4.4 Hylocereus polyrhizus-Induced Lipid-Lowering Activity -- 4.4.5 Chinese Wild Rice (Zizania latifolia) and North American Wild Rice (Zizania aquatica) Mediated -- 4.4.6 The Antioxidant Potential of Rice Bran Protein Hydrolysate -- 4.4.7 Nepeta deflersiana Mediated Antioxidant Potential -- 4.4.8 Antioxidant Potential of Nutritional Molecules -- 4.5 Potential Antioxidant-Based Experimental Interventions -- 4.6 Conclusion -- References -- Chapter 5 Antioxidant Therapy: A Promising Avenue for Regulating Inflammation in Psoriasis -- 5.1 Introduction -- 5.2 Pathogenesis of Psoriasis -- 5.3 Understanding Antioxidants -- 5.4 The Potential of Antioxidant Therapy in Psoriasis. 5.5 Clinical Trials and Evidence-Based Findings -- 5.6 Future Perspectives and Challenges -- 5.7 Conclusion -- References -- Chapter 6 Antioxidants in Infectious Disease Management -- 6.1 Introduction -- 6.2 Phytochemicals -- 6.3 Antioxidants -- 6.3.1 Classification of Antioxidants -- 6.3.2 Synthetic vs. Natural Antioxidants -- 6.3.3 Oxidative Stress -- 6.3.4 Characteristics of Antioxidants -- 6.3.5 Mechanism of Action of Antioxidants -- 6.3.6 Relevance of Antioxidants to Health -- 6.3.7 Some Undesirable Health-Related Effects of Antioxidants -- 6.4 Disease and Causes of Death -- 6.4.1 Infectious Disease -- 6.4.2 Coronavirus Disease (COVID-19) -- 6.4.2.1 Transmission of SARS-CoV-2 -- 6.4.2.2 Clinical Manifestations of COVID-19 -- 6.4.2.3 Treatment/Management of COVID-19 -- 6.4.3 Ebola Virus Disease (EVD) -- 6.4.3.1 Transmission of Ebola Virus -- 6.4.3.2 Clinical Features of EVD -- 6.4.3.3 Treatment of EVD -- 6.4.4 Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) -- 6.4.4.1 Transmission of HIV -- 6.4.4.2 Symptoms of HIV/AIDS -- 6.4.4.3 Treatment of HIV -- 6.4.5 Diphtheria -- 6.4.5.1 Transmission of Diphtheria -- 6.4.5.2 Treatment of Diphtheria -- 6.4.6 Influenza -- 6.4.6.1 Transmission of Influenza -- 6.4.6.2 Treatment/Management of Influenza -- 6.4.7 Measles -- 6.4.7.1 Symptoms of Measles -- 6.4.7.2 Transmission of Measles -- 6.4.7.3 Prevention/Treatment of Measles -- 6.4.8 Mumps -- 6.4.8.1 Symptoms of Mumps -- 6.4.8.2 Transmission of Mumps -- 6.4.8.3 Treatment for Mumps -- 6.4.9 Rubella -- 6.4.9.1 Transmission of Rubella Virus Disease -- 6.4.9.2 Symptoms of Rubella Virus Disease -- 6.4.9.3 Treatment of Rubella Virus Disease -- 6.4.10 Haemophilus influenzae Infections -- 6.4.11 Sexually Transmitted Diseases -- 6.4.12 Salmonella -- 6.4.12.1 Transmission of Salmonella -- 6.4.12.2 Symptoms of Salmonellosis. 6.4.12.3 Treatment of Salmonellosis -- 6.4.13 Cholera -- 6.4.13.1 Transmission of Cholera -- 6.4.13.2 Symptoms of Cholera -- 6.4.13.3 Treatment of Cholera -- 6.4.10.1 Causes of H. influenzae Infections -- 6.4.10.2 Transmission of H. influenzae Infections -- 6.4.10.3 Symptoms of H. influenzae Infection -- 6.4.10.4 Treatment of H. influenzae Infection -- 6.4.14 Hepatitis -- 6.4.14.1 Types of Hepatitis, Causes, Symptoms and Treatment -- 6.4.14.2 Hepatitis A -- 6.4.14.3 Hepatitis B -- 6.4.14.4 Hepatitis C -- 6.4.14.5 Hepatitis D -- 6.4.14.6 Hepatitis E -- 6.4.14.7 Hepatitis F and G -- 6.5 Bases of Use of Antioxidants in the Management of Infectious Diseases -- 6.6 Sources of Antioxidant Beneficial in the Management of Infectious Diseases -- 6.6.1 Resveratrol -- 6.6.2 Pinus Pinaster Bark Extract -- 6.6.3 Camellia sinensis -- 6.6.4 Allium cepa -- 6.6.5 Allium sativum -- 6.6.6 Aloe vera -- 6.6.7 Andrographis paniculata -- 6.6.8 Azadirachta indica -- 6.6.9 Curcuma longa -- 6.6.10 Glycyrrhiza glabra -- 6.7 Conclusion -- Acknowledgement -- References -- Chapter 7 Role of Antioxidant Therapy in Respiratory Disease Management -- 7.1 Introduction -- 7.1.1 Oxygen and its Evolution -- 7.1.2 Free Radicals -- 7.1.2.1 Free Radicals and Oxidative Stress -- 7.1.2.2 Role in Respiratory Diseases -- 7.1.2.3 Antioxidants and Respiratory Diseases -- 7.1.2.4 Potential Benefits -- 7.1.2.5 Limitations and Considerations -- 7.1.3 Defense Mechanism -- 7.1.3.1 Scavenging Reactive Oxygen Species (ROS) -- 7.1.3.2 Regeneration of Antioxidant Enzymes -- 7.1.3.3 Inhibition of Inflammatory Responses -- 7.1.3.4 Stabilization of Cell Membranes -- 7.1.3.5 Enhancement of Immune Function -- 7.2 Respiratory Diseases -- 7.2.1 Asthma -- 7.2.1.1 Etiology of Asthma -- 7.2.1.2 Pathophysiology of Asthma -- 7.2.2 Chronic Obstructive Pulmonary Disease (COPD) -- 7.2.2.1 Etiology of COPD. 7.2.2.2 Pathophysiology of COPD. |
| Record Nr. | UNINA-9911020174803321 |
Sindhu Rakesh K
|
||
| Newark : , : John Wiley & Sons, Incorporated, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Bioactive-Based Nanotherapeutics
| Bioactive-Based Nanotherapeutics |
| Autore | Sindhu Rakesh K |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Newark : , : John Wiley & Sons, Incorporated, , 2025 |
| Descrizione fisica | 1 online resource (771 pages) |
| Altri autori (Persone) |
SinghSumitra
YaparEvren Algin |
| ISBN |
1-394-28734-8
1-394-28733-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover -- Series Page -- Title Page -- Copyright Page -- Contents -- Preface -- Chapter 1 Basics of Nano-Bioactive Compounds and Their Therapeutic Potential -- 1.1 Introduction -- 1.2 Therapeutic Potential of Bioactive Compounds -- 1.2.1 Alkaloids -- 1.2.1.1 Medicinal Use of Alkaloids as Bioactive Molecule -- 1.2.2 Antibiotics -- 1.2.2.1 Medicinal Use of Antibiotics as Bioactive Molecule -- 1.2.3 Mycotoxins -- 1.2.3.1 Medicinal Use of Mycotoxins as Bioactive Molecule -- 1.2.4 Growth Factors -- 1.2.4.1 Medicinal Use of Growth Factors as Bioactive Compounds -- 1.2.5 Phenolics -- 1.2.5.1 Medicinal Use of Phenolics as Bioactive Compounds -- 1.3 Extraction Techniques for Obtaining Bioactive Compound -- 1.4 Novel Delivery Approach for Bioactive Compounds -- 1.5 Electrospinning -- 1.6 Micro- and Nanoencapsulation of Bioactive Compounds -- 1.7 Polymeric Nanoparticles (NPs) -- 1.8 Solid Lipid Nanoparticles -- 1.9 Nanoemulsions -- 1.10 Nanocrystals -- 1.11 Phytosomes -- 1.12 Therapeutic Potential of Nano-Bioactive Compounds -- 1.13 Conclusion -- References -- Chapter 2 Recent Techniques for Isolation of Bioactive Components from Plants -- 2.1 Introduction -- 2.2 Extraction Methods -- 2.2.1 Ultrasound-Assisted Extraction (UAE) -- 2.2.2 Supercritical Fluid Extraction (SFE) -- 2.2.3 Microwave-Assisted Extraction (MAE) -- 2.2.4 Molecular Imprinting Technology (MIT) -- 2.3 Recent Chromatographic Methods -- 2.3.1 Liquid Chromatography (LC) and Gas Chromatography (GC) -- 2.3.2 High-Performance Liquid Chromatography (HPLC) and Tandem Mass Spectrometry (MS/MS) -- 2.3.3 Supercritical Fluid Chromatography (SFC) -- 2.3.4 Two-Dimensional Chromatographic Approaches -- 2.4 Applications of Two-Dimensional Chromatographic Approaches -- 2.5 Hyphenated Techniques -- 2.6 Conclusion -- References -- Chapter 3 Bioactive-Based Nanocarriers for Inflammatory Diseases.
3.1 Inflammation and Diseases -- 3.2 Nanocarriers as Drug Delivery System -- 3.3 Nanocarriers and Inflammation -- 3.4 Inflammation in Central Nervous System -- 3.4.1 Etiology of CNS Inflammation -- 3.4.2 The Blood-Brain Barrier (BBB) -- 3.4.3 Immune Response -- 3.4.4 Clinical Manifestations -- 3.4.5 Diagnosis and Therapeutic Approaches -- 3.4.6 Chronic Inflammation -- 3.5 Ophthalmological Inflammation -- 3.5.1 Causes of Ophthalmological Inflammation -- 3.5.2 Symptoms of Ophthalmological Inflammation -- 3.5.3 Diagnosis and Treatment -- 3.6 Cardiovascular Inflammation -- 3.6.1 Significance of Inflammation -- 3.6.2 Factors Contributing to Inflammation -- 3.6.3 Role of Cytokines and Chemokines -- 3.6.4 Distinguishing Acute and Chronic Inflammation -- 3.6.5 Consequences of Chronic Inflammation -- 3.6.6 Treatment and Prevention -- 3.6.7 Use of Biomarkers -- 3.6.8 Ongoing Research -- 3.6.9 Nanocarriers Used in the Treatment of Cardiovascular Inflammation -- 3.7 Respiratory Inflammation -- 3.7.1 Origins of Respiratory Inflammation -- 3.7.2 Forms of Respiratory Inflammation -- 3.7.3 Disorders Associated with Respiratory Inflammation -- 3.7.4 Symptoms of Respiratory Inflammation -- 3.7.5 Treatment and Management -- 3.7.6 Prevention -- 3.7.7 Nanocarriers Used for the Treatment of Respiratory Inflammation -- 3.8 Inflammation in Gastric System -- 3.8.1 Causes of Gastric Inflammation -- 3.8.2 Types of Gastric Inflammation -- 3.8.3 Symptoms of Gastric Inflammation -- 3.8.4 Complications -- 3.8.5 Diagnosis -- 3.8.6 Treatment and Management -- 3.8.7 Prevention -- 3.8.8 Nanocarriers Used for the Treatment of Gastric Inflammation -- 3.9 Excretory System Inflammation -- 3.9.1 Causes of Excretory System Inflammation -- 3.9.2 Types of Urinary Tract Inflammation -- 3.9.3 Symptoms of Excretory System Inflammation -- 3.9.4 Complications -- 3.9.5 Diagnosis. 3.9.6 Treatment and Management -- 3.9.7 Prevention -- 3.9.8 Nanocarriers Used for Treatment of Excretory System Inflammation -- 3.10 Inflammation of the Reproductive System -- 3.10.1 Causes of Reproductive System Inflammation -- 3.10.2 Types of Reproductive System Inflammation -- 3.10.3 Symptoms of Reproductive System Inflammation -- 3.10.4 Complications -- 3.10.5 Diagnosis -- 3.10.6 Treatment and Management -- 3.10.7 Prevention -- 3.10.8 Nanocarriers Used for the Treatment of Reproductive Inflammation -- 3.11 Inflammation Associated with Dermatology -- 3.11.1 Causes of Dermatological Inflammation -- 3.11.2 Types of Dermatological Inflammation -- 3.11.3 Symptoms of Dermatological Inflammation -- 3.11.4 Complications -- 3.11.5 Diagnosis -- 3.11.6 Treatment and Management -- 3.11.7 Prevention -- 3.11.8 Nanocarriers Used for the Treatment of Inflammation Related to Dermatology -- 3.12 Muscular Inflammation -- 3.12.1 Causes of Muscular Inflammation -- 3.12.2 Types of Muscular Inflammation -- 3.12.3 Symptoms of Muscular Inflammation -- 3.12.4 Complications -- 3.12.5 Diagnosis -- 3.12.6 Treatment and Management -- 3.12.7 Prevention -- 3.12.8 Nanocarriers Used for the Treatment of Muscular Inflammation -- 3.13 Skeletal Inflammation -- 3.13.1 Causes of Skeletal Inflammation -- 3.13.2 Types of Skeletal Inflammation -- 3.13.3 Symptoms of Skeletal Inflammation -- 3.13.4 Complications -- 3.13.5 Diagnosis -- 3.13.6 Treatment and Management -- 3.13.7 Prevention -- 3.13.8 Nanocarriers Used for the Treatment of Skeletal Inflammation -- 3.14 Applications of Nanocarriers in Inflammation -- 3.15 Conclusion -- References -- Chapter 4 Bioactive-Based Nanocarriers for Dermal Diseases -- 4.1 Introduction -- 4.2 Skin Anatomy and Physiology: Implications for Drug Delivery -- 4.2.1 Structure of the Skin Layers -- 4.2.2 Epidermis: The Protective Barrier. 4.2.3 Dermis: Structural Support and Vascular Network -- 4.2.4 Hypodermis: Adipose Tissue and Insulation -- 4.2.5 Appendages: Hair Follicles, Sweat Glands, and More -- 4.3 Barrier Functions of the Skin -- 4.4 Transdermal Permeation Challenges -- 4.5 Factors Influencing Dermal Drug Penetration -- 4.5.1 Physicochemical Properties of the Drug -- 4.5.2 Formulation and Carrier Design -- 4.5.3 Skin Hydration and Moisture -- 4.5.4 Skin Integrity and Barrier Disorders -- 4.5.5 Anatomical Site and Skin Thickness -- 4.5.6 Circulation and Blood Flow -- 4.5.7 Skin pH and Microenvironment -- 4.6 Role of Nanocarriers in Enhancing Drug Penetration -- 4.6.1 Nanocarrier Types and Properties -- 4.6.2 Encapsulation and Solubilization -- 4.6.3 Enhanced Skin Penetration -- 4.6.4 Targeted Drug Delivery -- 4.6.5 Controlled Release -- 4.6.6 Safety and Biocompatibility -- 4.7 Types of Bioactive-Based Nanocarriers -- 4.8 Design Principles and Fabrication Techniques -- 4.8.1 Formulation Considerations -- 4.8.2 Techniques for Fabricating Bioactive-Based Nanocarriers -- 4.9 Characterization of Bioactive-Based Nanocarriers -- 4.9.1 Physicochemical Characterization -- 4.9.1.1 Dynamic Light Scattering -- 4.9.1.2 Zeta Potential Measurement -- 4.9.1.3 Fourier-Transform Infrared Spectroscopy -- 4.9.2 Morphological Analysis -- 4.9.2.1 Transmission Electron Microscopy -- 4.9.2.2 Scanning Electron Microscopy -- 4.9.3 Drug Release Profiling -- 4.9.3.1 In Vitro Release Studies -- 4.9.3.2 Franz Diffusion Cells -- 4.9.4 Stability Assessment -- 4.9.4.1 Accelerated Stability Studies -- 4.9.4.2 Thermal Analysis -- 4.10 Applications in Diverse Dermal Diseases -- 4.10.1 Acne: Targeted Delivery of Anti-Inflammatory Agents -- 4.10.1.1 Anti-Inflammatory Agents for Acne Treatment -- 4.10.1.2 Enhanced Drug Penetration -- 4.10.2 Psoriasis: Immune Modulation and Skin Barrier Restoration. 4.10.2.1 Immune Modulation Through Nanocarriers -- 4.10.2.2 Restoring Skin Barrier Function with Nanocarriers -- 4.10.2.3 Synergy in Action: Combined Approach for Comprehensive Psoriasis Management -- 4.10.3 Skin Cancers: Localized Chemotherapy and Photodynamic Therapy -- 4.10.4 Atopic Dermatitis: Addressing Inflammation and Pruritus -- 4.10.5 Bioactive-Based Nanocarriers for Chronic Wounds -- 4.11 Preclinical Studies: In Vivo and In Vitro -- 4.12 Challenges and Future Directions -- 4.13 Conclusion -- References -- Chapter 5 Nano-Based Nasal Delivery of Biomacromolecules: A Myriad of Opportunities -- 5.1 Biomacromolecules -- 5.2 Characteristics of Biomacromolecules and Delivery Challenges -- 5.2.1 Physicochemical Properties -- 5.2.2 Stability -- 5.2.3 Immunogenicity -- 5.2.4 Administration Route -- 5.3 Opportunities of Nasal Route -- 5.4 Main Factors in Nasal Cavity Affecting Delivery of Biomacromolecules -- 5.4.1 Nasal Epithelium and Absorption -- 5.4.2 Mucus Layer and Mucociliary Clearance -- 5.4.3 Enzymatic Activity -- 5.4.4 Other Factors -- 5.5 Nano-Based Delivery Systems as an Efficient Strategy to Improve Intranasal Administration of Biomacromolecules -- 5.5.1 Lipid-Based Delivery Systems -- 5.5.1.1 Liposomes -- 5.5.1.2 Lipid Nanoparticles: Solid Lipid Nanocarriers and Nanostructured Lipid Carriers -- 5.5.1.3 Nanoemulsions -- 5.5.2 Polymer-Based Delivery Systems -- 5.5.2.1 Polymeric Nanoparticles -- 5.5.2.2 Polymeric Micelles -- 5.5.2.3 Polymeric Nanocomplexes -- 5.5.2.4 Dendrimers -- 5.5.3 Inorganic Material-Based Delivery Systems -- 5.6 Proof of Concept: Biomacromolecules Administered by Intranasal Nano-Based Delivery Systems -- 5.6.1 Insulin -- 5.6.2 Glucagon-Like Peptide-1 and Its Analogs -- 5.6.3 Thyrotropin-Releasing Hormone -- 5.6.4 Other Peptides and Proteins -- 5.6.5 Nucleic Acid Therapeutics -- 5.7 Safety Considerations. 5.8 Conclusion. |
| Record Nr. | UNINA-9911019564903321 |
|
Sindhu Rakesh K
|
||
| Newark : , : John Wiley & Sons, Incorporated, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Herbal drugs for the management of infectious diseases
| Herbal drugs for the management of infectious diseases |
| Autore | Sindhu Rakesh K |
| Pubbl/distr/stampa | Newark : , : John Wiley & Sons, Incorporated, , 2022 |
| Descrizione fisica | 1 online resource (550 pages) |
| Altri autori (Persone) |
SinghInderbir
ShirkhedkarAtul A PanichayupakaranantPharkphoom |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-119-81877-X
1-119-81875-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910590092503321 |
|
Sindhu Rakesh K
|
||
| Newark : , : John Wiley & Sons, Incorporated, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||